Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CSII's Cash to Debt is ranked higher than
87% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. CSII: No Debt )
CSII' s 10-Year Cash to Debt Range
Min: 1.11   Max: No Debt
Current: No Debt

Equity to Asset 0.82
CSII's Equity to Asset is ranked higher than
87% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CSII: 0.82 )
CSII' s 10-Year Equity to Asset Range
Min: -1.4   Max: 0.94
Current: 0.82

-1.4
0.94
F-Score: 4
Z-Score: 21.78
M-Score: -1.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -20.29
CSII's Operating margin (%) is ranked higher than
59% of the 489 Companies
in the Global Medical Devices industry.

( Industry Median: 4.88 vs. CSII: -20.29 )
CSII' s 10-Year Operating margin (%) Range
Min: -7725.17   Max: 3.82
Current: -20.29

-7725.17
3.82
Net-margin (%) -20.45
CSII's Net-margin (%) is ranked higher than
60% of the 489 Companies
in the Global Medical Devices industry.

( Industry Median: 2.78 vs. CSII: -20.45 )
CSII' s 10-Year Net-margin (%) Range
Min: -7634.69   Max: 13.13
Current: -20.45

-7634.69
13.13
ROE (%) -21.57
CSII's ROE (%) is ranked higher than
59% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 3.65 vs. CSII: -21.57 )
CSII' s 10-Year ROE (%) Range
Min: -99.5   Max: 10
Current: -21.57

-99.5
10
ROA (%) -18.02
CSII's ROA (%) is ranked higher than
60% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. CSII: -18.02 )
CSII' s 10-Year ROA (%) Range
Min: -232.73   Max: 6.68
Current: -18.02

-232.73
6.68
ROC (Joel Greenblatt) (%) -134.62
CSII's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 5.54 vs. CSII: -134.62 )
CSII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4509.29   Max: 88.2
Current: -134.62

-4509.29
88.2
Revenue Growth (3Y)(%) -0.80
CSII's Revenue Growth (3Y)(%) is ranked higher than
66% of the 348 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. CSII: -0.80 )
CSII' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 23.9
Current: -0.8

0
23.9
EBITDA Growth (3Y)(%) 27.50
CSII's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CSII: 27.50 )
CSII' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 79.4
Current: 27.5

0
79.4
EPS Growth (3Y)(%) 21.30
CSII's EPS Growth (3Y)(%) is ranked higher than
89% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. CSII: 21.30 )
CSII' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.2   Max: 81.2
Current: 21.3

-66.2
81.2
» CSII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CSII Guru Trades in Q1 2014

Steven Cohen 415,582 sh (+144.56%)
Paul Tudor Jones 10,670 sh (+57.10%)
Jim Simons 45,800 sh (-51.59%)
» More
Q2 2014

CSII Guru Trades in Q2 2014

Steven Cohen 315,487 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 43,000 sh (-6.11%)
» More
Q3 2014

CSII Guru Trades in Q3 2014

Bill Frels 111,842 sh (New)
Jim Simons 136,800 sh (+218.14%)
Steven Cohen 464,800 sh (+47.33%)
» More
Q4 2014

CSII Guru Trades in Q4 2014

John Burbank 8,773 sh (New)
Bill Frels 118,422 sh (+5.88%)
Steven Cohen 426,000 sh (-8.35%)
Jim Simons 15,302 sh (-88.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Cardiovascular Systems Inc

Mairs & Power Small Cap Fund Comments on Cardiovascular Systems - Oct 20, 2014

During the quarter, the Fund added medical device maker Cardiovascular Systems (CSII), one of the few remaining small public medical device companies based in the Twin Cities. The company has a strong position in treating peripheral arterial disease with its proprietary atherectomy equipment. A recent approval in significantly calcified coronary arteries opens up a substantial new market opportunity that the company is working hard to commercialize.



From Mairs & Power Small Cap Fund Q3 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Cardiovascular Systems Inc

Mairs & Power Small Cap Fund Comments on Cardiovascular Systems
During the quarter, the Fund added medical device maker Cardiovascular Systems (CSII), one of the few remaining small public medical device companies based in the Twin Cities. The company has a strong position in treating peripheral arterial disease with its proprietary atherectomy equipment. A recent approval in significantly calcified coronary arteries opens up a substantial new market opportunity that the company is working hard to commercialize. Read more...

Ratios

vs
industry
vs
history
P/B 7.80
CSII's P/B is ranked lower than
55% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. CSII: 7.80 )
CSII' s 10-Year P/B Range
Min: 0.18   Max: 14.53
Current: 7.8

0.18
14.53
P/S 7.19
CSII's P/S is ranked higher than
50% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. CSII: 7.19 )
CSII' s 10-Year P/S Range
Min: 0.24   Max: 7.78
Current: 7.19

0.24
7.78
Current Ratio 4.77
CSII's Current Ratio is ranked higher than
84% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. CSII: 4.77 )
CSII' s 10-Year Current Ratio Range
Min: 1.27   Max: 17.17
Current: 4.77

1.27
17.17
Quick Ratio 4.31
CSII's Quick Ratio is ranked higher than
85% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. CSII: 4.31 )
CSII' s 10-Year Quick Ratio Range
Min: 1.18   Max: 17.17
Current: 4.31

1.18
17.17
Days Inventory 132.42
CSII's Days Inventory is ranked higher than
76% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 173.97 vs. CSII: 132.42 )
CSII' s 10-Year Days Inventory Range
Min: 37.97   Max: 122.32
Current: 132.42

37.97
122.32
Days Sales Outstanding 59.24
CSII's Days Sales Outstanding is ranked higher than
83% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 84.35 vs. CSII: 59.24 )
CSII' s 10-Year Days Sales Outstanding Range
Min: 51.75   Max: 310.37
Current: 59.24

51.75
310.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.00
CSII's Price/Net Cash is ranked higher than
87% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: 17.00 )
CSII' s 10-Year Price/Net Cash Range
Min: 0.54   Max: 231.2
Current: 17

0.54
231.2
Price/Net Current Asset Value 12.30
CSII's Price/Net Current Asset Value is ranked higher than
79% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CSII: 12.30 )
CSII' s 10-Year Price/Net Current Asset Value Range
Min: 0.53   Max: 27.54
Current: 12.3

0.53
27.54
Price/Tangible Book 8.10
CSII's Price/Tangible Book is ranked higher than
60% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 8.40 vs. CSII: 8.10 )
CSII' s 10-Year Price/Tangible Book Range
Min: 0.52   Max: 12.77
Current: 8.1

0.52
12.77
Price/Median PS Value 3.30
CSII's Price/Median PS Value is ranked higher than
52% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. CSII: 3.30 )
CSII' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 3.29
Current: 3.3

0.32
3.29
Earnings Yield (Greenblatt) -3.00
CSII's Earnings Yield (Greenblatt) is ranked higher than
61% of the 495 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. CSII: -3.00 )
CSII' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3   Max: 5408.1
Current: -3

-3
5408.1

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 184 245 327 407
EPS($) -1.03 -0.91 -0.02 1.76
EPS without NRI($) -1.03 -0.91 -0.02 1.76

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:R7Y1.Germany,
Cardiovascular Systems, Inc. was incorporated as Replidyne, Inc. in Delaware in 2000. On February 25, 2009, Replidyne, Inc. completed its business combination with Cardiovascular Systems, Inc., a Minnesota Corporation. At the effective time of the merger, Replidyne changed its name to Cardiovascular Systems, Inc. CSI is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Interventional endovascular treatment of peripheral artery disease, or PAD, was the initial area of focus. PAD is caused by the accumulation of plaque in peripheral arteries, most commonly occurring in the pelvis and legs, and affects approximately eight to 12 million people in the United States. Its initial product, the Diamondback 360(r) PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee and addresses many of the limitations associated with existing treatment alternatives. The Diamondback 360°'s single-use catheter incorporates a flexible drive shaft with an offset crown coated with diamond grit. With the aid of fluoroscopy, the physician positions the crown at a plaque-containing lesion in the peripheral artery and removes the plaque by causing the crown to orbit against it. This mechanism of action creates a smooth lumen, or channel, in the vessel. The Diamondback 360° is designed to differentiate between plaque and compliant arterial tissue, a concept known as 'differential sanding'. The Diamondback 360° sands plaque into small particles and restores both blood flow and vessel compliance. The particles created by the Diamondback 360° are generally smaller than red blood cells and are carried away by the bloodstream. The small size of the particles avoids the need for plaque collection reservoirs. The Diamondback 360° could treat the diseased arteries with less than three minutes of sanding time, potentially reducing the overall procedure time. In addition to the Diamondback 360°, the Company is expanding its product portfolio through internal product development and establishment of business relationships. CSI now offers multiple accessory devices designed to complement the use of the Diamondback 360°, and have entered into distribution agreements with Invatec, Inc. and Asahi-Intecc, Ltd. CSI markets and sells the Diamondback 360° through a direct sales force in the United States. The Company target its marketing efforts to practitioners through physician education, medical conferences, seminars, peer reviewed journals and marketing materials. The medical device industry is highly competitive, subject to rapid change and is affected by new product introductions and other activities of industry participants. The competitors in the stent and balloon angioplasty market segments include Abbott Laboratories, Boston Scientific, Cook, Johnson & Johnson and Medtronic. The Company also compete against manu
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Mairs & Power Small Cap Fund Comments on Cardiovascular Systems Oct 20 2014 
Mairs & Power Small Cap Fund Q3 2014 Commentary Oct 20 2014 
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley sells 5,663 Shares May 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) May 14 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Feb 12 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 16 2009 


More From Other Websites
Cardiovascular Systems Receives FDA Clearance for New Peripheral Diamondback Device Apr 20 2015
Cardiovascular Systems Receives FDA Clearance for New Peripheral Diamondback Device Apr 20 2015
Cardiovascular Systems to Webcast Fiscal 2015 Third-Quarter Earnings Conference Call Wednesday,... Apr 09 2015
Cardiovascular Systems to Webcast Fiscal 2015 Third-Quarter Earnings Conference Call Wednesday,... Apr 08 2015
Boston Scientific Boosts Endoscopy Business, Buys Xlumena - Analyst Blog Apr 07 2015
NxStage Medical Opens New Dialysis Center in Maryland - Analyst Blog Apr 01 2015
Zacks Rank #1 Additions for Wednesday - Tale of the Tape Apr 01 2015
Why Omeros (OMER) Could Be Positioned for a Slump - Tale of the Tape Apr 01 2015
Zimmer-Biomet Deal Gets European Commission's Approval - Analyst Blog Mar 31 2015
Zimmer Unveils External Fixation System, Expands in Trauma - Analyst Blog Mar 30 2015
Will Cardiovascular Systems (CSII) Crush Estimates at Its Next Earnings Report? - Tale of the Tape Mar 26 2015
Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capital’s Winning Bets... Mar 19 2015
Merge's DR Systems Buyout Inspires Despite Q4 Revenue Lag - Analyst Blog Mar 09 2015
The Zacks Analyst Blog Highlights: Medtronic, Abaxis, Vascular Solutions and Cardiovascular Systems... Mar 06 2015
Medtronic Positive on Covidien Integration, Potential Synergy - Analyst Blog Mar 05 2015
Cardiovascular Systems to Present at Barclays 2015 Global Healthcare Conference Mar 04 2015
Cardiovascular Systems to Present at Barclays 2015 Global Healthcare Conference Mar 04 2015
Bioscrip Q4 Loss Wider than Expected, Revenues Up Y/Y - Analyst Blog Mar 04 2015
CARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 03 2015
Boston Scientific to Buy Endo International's Urology Business - Analyst Blog Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK